David F. Schneider, MD, MS, FACS
- Division of Endocrine Surgery
- Divisions of General Surgery
600 Highland Ave
BX7375 Clinical Science Center
Madison, WI 53792-3284
- MD, Loyola Stritch School of Medicine, Chicago, IL, 2004
- Research Fellowship in Burn & Shock Trauma, Loyola Medical Center, Chicago, IL, 2008
- MS in Clinical Research Methods, Department of Preventive Medicine & Epidemiology, Loyola Stritch School of Medicine, 2010
- General Surgery Residency, Loyola Medical Center, Chicago, IL, 2011
- Fellowship in Endocrine Surgery, University of Wisconsin School of Medicine and Public Health, 2013
Dr. Schneider is certified by the American Board of Surgery, and he is a member of multiple specialty societies including the American Association of Endocrine Surgeons, the American Thyroid Association, the North American NeuroEndocrine Tumor Society, and the American Association of Clinical Endocrinologists. He specializes in endocrine surgery, treating diseases of the thyroid, parathyroid, and adrenal glands. He utilizes several minimally invasive techniques to treat endocrine disorders (endoscopic thyroidectomy, minimally invasive parathyroidectomy, laparoscopic adrenalectomy, focused exploration for recurrent thyroid cancer).
Dr. Schneider provides a wide range of services including Adrenal Surgery, Central Neck Dissection, Endocrine Surgery, Fine Needle Aspiration (FNA), Laparoscopic Adrenalectomy, Minimally Invasive Parathyroidectomy, Minimally Invasive Radioguided Parathyroidectomy (MIRP), Modified Radical Neck Dissection, Neck Ultrasound, Open Adrenalectomy, Parathyroid Surgery, Resection Of Substernal Goiter, Retroperitoneoscopic Adrenalectomy, Subtotal Parathyroidectomy, Thyroidectomy, Thyroid Lobectomy, Thyroid Surgery, Total Thyroidectomy.
Dr. Schneider conducts outcomes research in conjunction with the Wisconsin Surgical Outcomes Program. His research program investigates the optimization of cancer care in the United States with a particular interest in endocrine cancers. This work utilizes large national databases which can impact national healthcare and policy initiatives. He also conducts clinical research working on hyperparathyroidism, thyroid cancer, Graves’ Disease, and adrenal disorders.
- Survival in patients with medullary thyroid cancer after less than the recommended initial operation.
- Randle RW, Bates MF, Schneider DF, Sippel RS, Pitt SC
- J Surg Oncol 2017 Dec 19;
- [PubMed ID: 29266278]
- Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?
- Bates MF, Lamas MR, Randle RW, Long KL, Pitt SC, Schneider DF, Sippel RS
- Surgery 2018 Jan; 163(1): 118-123
- [PubMed ID: 29128176]
- Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.
- Balentine CJ, Vanness DJ, Schneider DF
- Surgery 2018 Jan; 163(1): 88-96
- [PubMed ID: 29128178]
- Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty.
- Randle RW, Bates MF, Long KL, Pitt SC, Schneider DF, Sippel RS
- Surgery 2018 Jan; 163(1): 68-72
- [PubMed ID: 29108701]
- MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
- Chu YH, Hardin H, Schneider DF, Chen H, Lloyd RV
- Exp. Mol. Pathol. 2017 10; 103(2): 229-236
- [PubMed ID: 29107050]